146 related articles for article (PubMed ID: 15343513)
1. Loss of heterozygosity reveals non-VHL allelic loss in hemangioblastomas at 22q13.
Beckner ME; Sasatomi E; Swalsky PA; Hamilton RL; Pollack IF; Finkelstein SD
Hum Pathol; 2004 Sep; 35(9):1105-11. PubMed ID: 15343513
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas.
Lee JY; Dong SM; Park WS; Yoo NJ; Kim CS; Jang JJ; Chi JG; Zbar B; Lubensky IA; Linehan WM; Vortmeyer AO; Zhuang Z
Cancer Res; 1998 Feb; 58(3):504-8. PubMed ID: 9458097
[TBL] [Abstract][Full Text] [Related]
3. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
4. Molecularly genetic analysis of von Hippel-Lindau associated central nervous system hemangioblastoma.
Zhou J; Wang J; Li N; Zhang X; Zhou H; Zhang R; Ma H; Zhou X
Pathol Int; 2010 Jun; 60(6):452-8. PubMed ID: 20518900
[TBL] [Abstract][Full Text] [Related]
5. Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system.
Takayanagi S; Mukasa A; Tanaka S; Nomura M; Omata M; Yanagisawa S; Yamamoto S; Ichimura K; Nakatomi H; Ueki K; Aburatani H; Saito N
Neuro Oncol; 2017 Sep; 19(9):1228-1236. PubMed ID: 28379443
[TBL] [Abstract][Full Text] [Related]
6. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.
Gläsker S; Bender BU; Apel TW; van Velthoven V; Mulligan LM; Zentner J; Neumann HP
J Neurol Neurosurg Psychiatry; 2001 May; 70(5):644-8. PubMed ID: 11309459
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Marti HH; Plate KH
Blood; 1998 Nov; 92(9):3388-93. PubMed ID: 9787178
[TBL] [Abstract][Full Text] [Related]
8. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease.
Vortmeyer AO; Gnarra JR; Emmert-Buck MR; Katz D; Linehan WM; Oldfield EH; Zhuang Z
Hum Pathol; 1997 May; 28(5):540-3. PubMed ID: 9158701
[TBL] [Abstract][Full Text] [Related]
9. Developmental effects of von Hippel-Lindau gene deficiency.
Vortmeyer AO; Yuan Q; Lee YS; Zhuang Z; Oldfield EH
Ann Neurol; 2004 May; 55(5):721-8. PubMed ID: 15122713
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
11. Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity.
Gijtenbeek JM; Jacobs B; Sprenger SH; Eleveld MJ; van Kessel AG; Kros JM; Sciot R; van Calenbergh F; Wesseling P; Jeuken JW
J Neurosurg; 2002 Oct; 97(4):977-82. PubMed ID: 12405390
[TBL] [Abstract][Full Text] [Related]
12. Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.
Taïeb D; Barlier A; Yang C; Pertuit M; Tchoghandjian A; Rochette C; Zattara-Canoni H; Figarella-Branger D; Zhuang Z; Pacak K; Metellus P
J Neurooncol; 2016 Feb; 126(3):473-81. PubMed ID: 26514359
[TBL] [Abstract][Full Text] [Related]
13. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL
Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619
[TBL] [Abstract][Full Text] [Related]
14. Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene.
Muscarella LA; Bisceglia M; Galliani CA; Zidar N; Ben-Dor DJ; Pasquinelli G; la Torre A; Sparaneo A; Fanburg-Smith JC; Lamovec J; Michal M; Bacchi CE
Pathol Res Pract; 2018 Aug; 214(8):1156-1165. PubMed ID: 29941223
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors.
Hunt JL; Yim JH; Tometsko M; Finkelstein SD; Swalsky P; Carty SE
Surgery; 2003 Dec; 134(6):1043-7; discussion 1047-8. PubMed ID: 14668739
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity at 6q is frequent and concurrent with 3p loss in sporadic and familial capillary hemangioblastomas.
Lemeta S; Pylkkänen L; Sainio M; Niemelä M; Saarikoski S; Husgafvel-Pursiainen K; Böhling T
J Neuropathol Exp Neurol; 2004 Oct; 63(10):1072-9. PubMed ID: 15535134
[TBL] [Abstract][Full Text] [Related]
17. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.
Chan CC; Collins AB; Chew EY
Retina; 2007 Jan; 27(1):1-7. PubMed ID: 17218907
[TBL] [Abstract][Full Text] [Related]
19. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma.
Grebe SK; McIver B; Hay ID; Wu PS; Maciel LM; Drabkin HA; Goellner JR; Grant CS; Jenkins RB; Eberhardt NL
J Clin Endocrinol Metab; 1997 Nov; 82(11):3684-91. PubMed ID: 9360526
[TBL] [Abstract][Full Text] [Related]
20. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
